ARPC3

Across TCGA pan-cancer cohorts, ARPC3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARPC3 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ARPC3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARPC3 expression acts as an unfavorable survival marker.

LUAD, GBM, and CCRCC are the cancer types where ARPC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.290	0.818	.016	13	view →
GBM	DFS	Tertile	All	0.679	0.873	.009	12	view →
CCRCC	OS	Median	All	0.833	0.955	.012	7	view →
PDAC	DFS	Tertile	IV	0.199	0.715	.024	6	view →
HNSC	OS	Median	All	0.958	1.000	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARPC3–LUAD (DFS)

Open the LUAD breakdown →